MG-262

Overview

MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1 . MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS) . MG-262 can be used for anti-cancer study.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Proteasome | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-108551
• CAS No.: 179324-22-2
• Molecular Formula: C25H42BN3O6
• Molecular Weight: 491.43
• Purity: 95.0%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source